cervical cancer
Conditions
Interventions
intervention arm:After admission, CT/MR and gynecological examination were performed to identify the clinical stage, pathological consultation or biopsy was performed to identify the pathological type
the second and third courses were paclitaxel 135-175 mg/m2 + carboplatin AUC = 5-6 + PD-1 monoclonal antibody 200 mg intravenous therapy. Every 21 days as a cycle, imaging was performed after three co
Sponsors
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. IB3-IIB pathologically diagnosed as squamous cell carcinoma, adenosquamous carcinoma, and common adenocarcinoma in our hospital, and stage IIB cervical cancer with a tumor diameter > 4 cm, and had not received any previous treatment. 2. Age between 18 and 80 years. 3. had complete clinical and pathological data. 4. ECOG score 0-1. 5. Patients voluntarily participated in this study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1 Patients with a previous history of other malignancies. 2 Patients with incomplete clinical data or treatment information. 3 Patients with serious comorbidities or inability to complete follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;progression-free survival;incidence of treatment-related adverse events;Impact of treatment on the tumor microenvironment;Impact of treatment on the gene expression profiles; | — |
Countries
China
Contacts
Public ContactHuaiwu Lu
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou
Outcome results
None listed